We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
YESCARTA (Gilead Sciences Pty Ltd)
Product name
YESCARTA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
199 working days (255)
Active ingredients
T Cells - axicabtagene ciloleucel, cryopreserved - T - Yescarta
Registration type
Biologicals
Indication
Class 4 biological
YESCARTA is a genetically modified autologous immunocellular therapy for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.